Another transporter, solute carrier family 1, member 5 (encoded by SLC1A5/ASCT2), the main pathway for glutamine entry into cells [122], is induced by HIF-2α under hypoxic conditions to promote glutamate-dependent ATP production and GSH synthesis, which renders pancreatic cancer cells resistant to gemcitabine [158], and the amphireguli/MEK/ERK/NRF2 signaling pathway can positively upregulate SLC1A5 to support cisplatin resistance in chondrosarcoma [159]. Here, SLC1A5 is linked to pancreatic neoplasm.